MTST News Alert Metastat Inc (MTST) 0.7600 09/27/2014 22:13:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Metastat Inc (MTST) 0.7600 $MTST

MetaStat to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference on September 11
Business Wire - Thu Sep 04, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, announced that Oscar L. Bronsther, M.D., Chief Executive Officer, is scheduled to speak at the Aegis Capital Corp. 2014 Healthcare & Technology Conference on September 11 at 3:30 PM PDT. Dr. Bronsther will be providing an overview of the Company and its business activities.

MetaStat to Present at Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014
Business Wire - Thu Aug 28, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, announced that Oscar L. Bronsther, M.D., Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw 16th Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 10, 2014 at 2:05 pm EDT. Dr. Bronsther will provide an update on the Company's business activities.

MetaStat, Inc. Announces Memorandum of Understanding to Transfer its Therapeutic Business
ACCESSWIRE - Thu Jul 17, 8:25AM CDT
MONTCLAIR, NJ. / ACCESSWIRE / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that on July 14, 2014 it entered into a binding Memorandum of Understanding (MOU) to transfer its therapeutic assets to a newly formed private company, ASET Therapeutics. ASET will be led by David Epstein, former chief scientific officer of OSI Pharmaceuticals, who will remain as a director of MetaStat for at least 6 months following consummation of the transaction.

ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc.
PR Newswire - Mon Jul 14, 7:00AM CDT
Today, ATS Labs, Inc. (ATS), majority owned by Ampersand Capital Partners, announced that it acquired the assets of MicroTest Labs, Inc. (MTL) of Agawam, MA. The acquisition of MTL is the first step in the strategy of ATS to expand its microbiology and chemistry laboratory services platform to support the medical device and biopharmaceutical industries. The combined companies will soon be known as Accuratus Lab Services, a name that personifies the quality and accuracy of testing results and scientific solutions that support the antimicrobial, consumer product, medical device, and biopharmaceutical industries.

MetaStat, Inc. Closes Equity Financing
ACCESSWIRE - Wed Jul 02, 11:18AM CDT
MONTCLAIR, NJ / ACCESSWIRE / July 2, 2014 / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that on June 30, 2014, it entered into a securities purchase agreement in a private placement totaling $5.7 million, inclusive of the automatic exchange of outstanding convertible promissory notes in the aggregate principal amount of approximately $3.3 million.

Photo Release -- Fish Embryo Toxicology Testing is Better Alternative for Whole-Effluent Testing, Advises New Whitepaper from Microtest Laboratories
GlobeNewswire - Mon Jun 16, 9:38AM CDT
As pharmaceutical, chemical and other manufacturers come under increased scrutiny for their Whole Effluent Toxicity (WET), a new methodology to measure WET -- fish embryo toxicity (FET) testing -- promises to better determine the potential environmental impact of their products and waste water on the environment.

MetaStat, Inc. Announces Issuance of New U.S. Patent for its MetaSite Breast(tm) Test
ACCESSWIRE - Thu Mar 06, 7:41AM CST
MONTCLAIR, N.J. / ACCESSWIRE / March 6, 2014 / MetaStat, Inc. (OTCQB : MTST), a life science company focused on understanding and treating systemic metastasis, announced today that the United States Patent and Trademark Office (USPTO) issued on February 4, 2014, U.S. Patent No. 8,642,277 entitled: "TUMOR MICROENVIRONMENT OF METASTASIS (TMEM) AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS." The named inventors of this new patent are John Condeelis, Thomas E. Rohan, Frank B. Gertler, and Joan G Jones.

MetaStat, Inc. to Present at the 26th Annual ROTH Conference
Marketwire - Wed Feb 26, 6:15AM CST
MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California. MetaStat will be presenting on Wednesday, March 12, 2014 at 12:30 pm (PT).

Rightscorp Innovative Business Model Persuades File Sharing Users to Pay Intellectual Property Holders: Updates on Recent Coverage
PR Newswire - Tue Feb 25, 6:00AM CST
A California company, Rightscorp, Inc. (OTCQB: RIHT) is receiving the blessing of major music and movie studios by going after illegal distributors on file-sharing sites in a different way than previous enforcement methods. Shareholders seem encouraged as well, especially since this type of low-level piracy is likely to continue.

Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.

Metastat Analyst Report Provides Investor Opportunity
PR Newswire - Mon Feb 17, 6:00AM CST
With the tremendous run in the biotech sector over the last 12 months many have overlooked this micro-cap gem that has terrific upside potential. Metastat, Inc. (OTCQB: MTST) is a life sciences company that provides proprietary platform technologies for the treatment of systemic metastasis. This micro-cap stock is topping the list for many analyst in the coming year.

MetaStat, Inc. Launches Scientific Advisory Board for Therapeutics
ACCESSWIRE - Mon Feb 10, 7:00AM CST
MONTCLAIR, NJ / ACCESSWIRE / February 10, 2014 / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced the appointments of scientific and clinical leaders from the fields of RNA biology, alternative splicing, and therapeutic resistance in cancer to its newly formed scientific advisory board for therapeutics. The members include David M. Epstein, Ph.D, Eric Winer, M.D., Adrian Krainer, Ph.D., Mariano-Garcia Blanco, M.D., Ph.D., Michael Hemann, M.D., Ph.D. and Frank Gertler, Ph.D.

MetaStat, Inc. to Present at the 2014 BIO CEO & Investor Conference in New York City on February 11, 2014
ACCESSWIRE - Wed Feb 05, 8:03AM CST
MONTCLAIR, NJ / February 5, 2014 / ACCESSWIRE / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that the company's Chief Executive Officer, Oscar Bronsther, M.D., will present at the BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 1:30 p.m. EST. The conference will be held at the Waldorf Astoria in New York. Dr. Bronsther will discuss MetaStat's novel diagnostic and therapeutic approaches to systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body.

Fundamentals of Endotoxin Testing for Medical Device Manufacturers are Detailed in New Technical Brief
Business Wire - Tue Jan 14, 9:12AM CST
The fundamentals of endotoxin testing for medical device manufacturers -- from definition to assay acceptance criteria --are detailed in new technical brief available from Microtest Laboratories.

Fidelity & Guaranty Life Holdings, Inc. Announces Year End 2013 Conference Call for Bondholders
PR Newswire - Tue Jan 07, 8:52AM CST
Fidelity & Guaranty Life Holdings, Inc. ("FGLH" today announced the date and time of its quarterly bondholder conference call for the Fiscal year ended September 30, 2013. The call is open to all holders of Fidelity & Guaranty Life Holdings, Inc. 6.375% senior unsecured notes due 2021.

MetaStat Announces Commencement of Its Comprehensive Drug Development Program with Significant New Hires and Research Facility Opening
ACCESSWIRE - Tue Sep 10, 6:05AM CDT
Montclair, NJ, (Accesswire - September 10, 2013) - MetaStat Inc. (OTCBB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that it has commenced its comprehensive drug development program with the hiring of Elizabeth Buck, Ph.D. and Matthew O'Connor, both formerly of OSI Pharmaceuticals, Inc. (acquired by Astellas Pharma, Inc.), along with the opening of its new drug discovery research facility located in Stony Brook, NY. Both Dr. Buck and Mr. O'Connor will work closely and in collaboration with Dr. David Epstein, MetaStat's Head of Drug Development and former Chief Scientific Officer of OSI Pharmaceuticals.

New Medical Device Polymer Biocompatibility Screening Test Using Zebrafish Embryos to be Discussed at AMI's Medical Grade Polymers 2013
Business Wire - Tue Sep 03, 9:13AM CDT
A new test that utilizes Zebrafish (Danio rerio) embryos to screen plastics, composites, and polymers for toxicity in medical device manufacturing will be featured at AMI's Medical Grade Polymer 2013 technical conference in September.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 0

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 34

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 16

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 76

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 33

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 54

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 15

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: Join Class Action Against Vestis Corporation

Updated Category News Views 240

Important Notice for Investors in Vestis Corporation Levi & Korsinsky, LLP is reaching out to those who have invested in Vestis Corporation (NYSE: VSTS) regarding a significant class action securities lawsuit. This initiative is intended for individuals who believe they faced losses as a consequence of the alleged securities fraud involving the company. Understanding the...

Continue Reading
Wegovy's Impact on MASH Care: Insights into Physician Adoption

Updated Category News Views 168

Wegovy's Revolutionary Role in MASH Treatment Wegovy, known in the medical community as semaglutide 2.4mg, has recently garnered approval as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). This development is viewed as a crucial advancement for a condition that affects a substantial patient population. With significant unmet needs, the...

Continue Reading
Opportunity for Orthofix Investors to Join Class Action Lawsuit

Updated Category News Views 248

Class Action Lawsuit Opportunity for Orthofix Investors Investors in Orthofix Medical Inc. have been alerted to a significant opportunity. A class action lawsuit is underway against Orthofix, involving allegations against current and former officers for violations of federal securities laws. If you are among those who encountered substantial losses due to the handling of...

Continue Reading
Meta Strengthens AI Infrastructure with Rivos Acquisition

Updated Category News Views 252

Meta Platforms Aims for AI Dominance Meta Platforms (NASDAQ:META) is making significant strides in the realm of artificial intelligence, channeling resources into massive chip investments and potential acquisitions to bolster its infrastructure. As one of the giants in U.S. technology, Meta is set on further establishing its presence in AI technology with a commitment of...

Continue Reading
Renovating Older Homes? Structural Insight is Key

Updated Category News Views 28

Unearthing the Bones of Older Homes It ain't rocket science to realize that before you swing a sledgehammer in an old house, you’d better know what you’re dealing with. The walls might look like just a bunch of paint and plaster, but underneath, they tell stories older than most of us. It's all laid out in this HelloNation chat with Jason Marks from Ward Construction....

Continue Reading